Management of Eliquis Before Dental Procedures in Factor V Leiden Patients
For most routine dental procedures, you should continue Eliquis without interruption and use local hemostatic measures to control bleeding. 1
Decision Framework
The key question is whether this is a simple dental procedure (single/multiple extractions, root canal, cleaning) or a complex oral surgery with higher bleeding risk.
For Simple Dental Procedures (Most Common Scenario)
Continue Eliquis 5 mg twice daily without interruption. The evidence strongly supports this approach:
- Guidelines for warfarin (VKA) therapy demonstrate that continuation with pro-hemostatic agents is safer than interruption, with no significant increase in bleeding risk 1
- While these guidelines specifically address warfarin, the same principles apply to DOACs like apixaban for low-bleeding-risk procedures 2
- Any bleeding that occurs is typically self-limiting and easily managed with local measures 1, 3
Use local hemostatic measures:
- Tranexamic acid mouthwash (10 mL of 5% solution) immediately before procedure and 2-3 times daily for 1-2 days post-procedure 1
- Extra sutures, gauze packing, topical hemostatic agents
- Minimize surgical trauma
For Higher-Risk Dental Procedures
If the procedure involves extensive oral surgery, multiple extractions with poor gingival health, or significant anticipated bleeding 1:
Hold Eliquis for 24-48 hours before the procedure:
- The FDA label states: "ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding" 4
- For moderate-to-high bleeding risk procedures: discontinue at least 48 hours prior 4
- Given apixaban's half-life of 9-14 hours, 24 hours provides approximately 2 half-lives of clearance; 48 hours provides approximately 3-4 half-lives 5
No bridging anticoagulation is needed - the FDA label explicitly states "Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required" 4
Factor V Leiden Consideration
Your patient has heterozygous Factor V Leiden (since they're on standard 5 mg dosing, not high-risk thrombophilia dosing). This is classified as:
- "Nonsevere coagulopathy" per the 2024 AHA/ACC guidelines 5
- Low-to-moderate thromboembolic risk for VTE recurrence 5
Recent evidence suggests Factor V Leiden may actually be protective against bleeding while on anticoagulation (HR 0.73 for major/CRNM bleeding) 6. This means:
- The thrombotic risk from stopping Eliquis is not elevated compared to other anticoagulated patients
- The bleeding risk while continuing Eliquis may be lower than in patients without thrombophilia
- This further supports continuing anticoagulation for routine dental work
Resumption of Therapy
Restart Eliquis as soon as adequate hemostasis is established - typically the same evening or next morning after the procedure 4. Do not wait days to restart.
Critical Pitfalls to Avoid
- Do not stop Eliquis for simple dental cleaning, fillings, or single extractions - the thromboembolic risk outweighs minimal bleeding risk 3, 2
- Do not use bridging anticoagulation - this increases bleeding risk without reducing thrombotic risk 4
- Do not delay restarting Eliquis - resume once bleeding is controlled, not after arbitrary time periods
- Coordinate with the prescribing physician if you're uncertain about procedure complexity 4
The Factor V Leiden mutation in this context is actually reassuring rather than concerning - it doesn't increase the need for continuous anticoagulation during brief interruptions and may reduce bleeding risk.